Tamoxifen for the treatment of malignancies other than breast and endometrial carcinoma

Research output: Contribution to journalReview articlepeer-review

92 Scopus citations

Abstract

Tamoxifen has been used most commonly to treat breast and endometrial cancer, two malignancies in which the antiestrogenic properties of tamoxifen have substantial therapeutic benefit. However, tamoxifen has been used in the treatment of other cancers as well, some in which an antiestrogen may be effective, but others in which estrogen receptor is not expressed. In estrogen receptor-negative cancers, tamoxifen has been shown to have therapeutic activity at doses approximately fourfold to eightfold above those used for estrogen receptor inhibition. It is thought that the primary mechanism of tamoxifen in estrogen-negative tumors is inhibition of protein kinase C. Clinical trials of tamoxifen in ovarian cancer, hepatocellular carcinoma, desmoid tumors, malignant glioma, pancreatic carcinoma, melanoma, and renal cell carcinoma are reviewed.

Original languageEnglish (US)
Pages (from-to)S1-65-S1-70
JournalSeminars in Oncology
Volume24
Issue numberSUPPL. 1
StatePublished - 1997
Externally publishedYes

ASJC Scopus subject areas

  • Hematology
  • Oncology

Fingerprint

Dive into the research topics of 'Tamoxifen for the treatment of malignancies other than breast and endometrial carcinoma'. Together they form a unique fingerprint.

Cite this